Aurinia Pharmaceuticals Inc
NASDAQ:AUPH

Watchlist Manager
Aurinia Pharmaceuticals Inc Logo
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Watchlist
Price: 8.71 USD Market Closed
Market Cap: 1.2B USD
Have any thoughts about
Aurinia Pharmaceuticals Inc?
Write Note

Aurinia Pharmaceuticals Inc
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Aurinia Pharmaceuticals Inc
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Other Equity
-$385k
CAGR 3-Years
22%
CAGR 5-Years
14%
CAGR 10-Years
7%
B
Bright Minds Biosciences Inc
CNSX:DRUG
Other Equity
-CA$33.7k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Other Equity
$860k
CAGR 3-Years
-40%
CAGR 5-Years
-28%
CAGR 10-Years
24%
Repare Therapeutics Inc
NASDAQ:RPTX
Other Equity
$28k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Covalon Technologies Ltd
XTSX:COV
Other Equity
CA$3.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
31%
Spectral Medical Inc
TSX:EDT
Other Equity
CA$11.3m
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
12%
No Stocks Found

Aurinia Pharmaceuticals Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company is headquartered in Victoria, British Columbia and currently employs 300 full-time employees. The company went IPO on 2001-07-16. The firm is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The firm has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. The company also focuses on treatment of autoimmune, fibrotic, and kidney-related diseases. Its product pipeline includes AUR200, AUR300.

AUPH Intrinsic Value
12.04 USD
Undervaluation 28%
Intrinsic Value
Price

See Also

What is Aurinia Pharmaceuticals Inc's Other Equity?
Other Equity
-385k USD

Based on the financial report for Sep 30, 2024, Aurinia Pharmaceuticals Inc's Other Equity amounts to -385k USD.

What is Aurinia Pharmaceuticals Inc's Other Equity growth rate?
Other Equity CAGR 10Y
7%

Over the last year, the Other Equity growth was 57%. The average annual Other Equity growth rates for Aurinia Pharmaceuticals Inc have been 22% over the past three years , 14% over the past five years , and 7% over the past ten years .

Back to Top